<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728078</url>
  </required_header>
  <id_info>
    <org_study_id>RFA005</org_study_id>
    <nct_id>NCT00728078</nct_id>
  </id_info>
  <brief_title>Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma</brief_title>
  <acronym>LDT-RFA</acronym>
  <official_title>Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the investigators' study is to prospectively evaluate whether low-dose
      thalidomide adjuvant therapy will improve the outcome of radiofrequency ablation for
      hepatocellular carcinoma (HCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our previous studies showed that radiofrequency ablation (RFA) was as effective as liver
      resection for small hepatocellular carcinoma (HCC), but the recurrence rates after RFA were
      relatively high. Adjuvant therapies maybe reduce the recurrence rate. Phase 1 and 2 studies
      showed that thalidomide was a safety and effective treatment for HCC, especially for small
      HCC with liver cirrhosis. So we proposed that low-dose thalidomide adjuvant therapy will
      improve the disease progress free survivals and overall survivals after RFA for HCC.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progress free survival</measure>
    <time_frame>1,3,5-year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>morbility</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1,3,5-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence rate</measure>
    <time_frame>1,3,5-year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low-dose thalidomide adjuvant therapy after RFA for HCC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>thalidomide 50mg tid for 6 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 75 years, who refused surgery or first recurrence after hepatectomy

          -  A solitary HCC 3.1-7.0cm in diameter, or 2-3 lesions, sums of diameters â‰¤ 7.0cm

          -  Lesions being visible on ultrasound (US) and with an acceptable/safe path between the
             lesion and the skin as shown on US

          -  No extrahepatic metastasis

          -  No imaging evidence of invasion into the major portal/hepatic vein branches

          -  No history of encephalopathy, ascites refractory to diuretics or variceal bleeding

          -  A platelet count of &gt; 40,000/mm3

          -  No previous treatment of HCC except liver resection

        Exclusion Criteria:

          -  Patient compliance is poor

          -  Previous or concurrent cancer that is distinct in primary site or histology from HCC,
             EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder
             tumors (Ta, Tis &amp; T1). Any cancer curatively treated &gt; 3 years prior to entry is
             permitted

          -  History of cardiac disease:

               -  congestive heart failure &gt; New York Heart Association (NYHA) class 2

               -  active coronary artery disease (myocardial infarction more than 6 months prior to
                  study entry is permitted)

               -  cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers,
                  *calcium channel blocker or digoxin

               -  uncontrolled hypertension (failure of diastolic blood pressure to fall below 90
                  mmHg, despite the use of 3 antihypertensive drugs)

          -  Active clinically serious infections (&gt; grade 2 National Cancer Institute [NCI]-Common
             Terminology Criteria for Adverse Events [CTCAE] version 3.0)

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Known Central Nervous System tumors including metastatic brain disease

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry

          -  Distantly extrahepatic metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>min-shan chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>min-shan chen, MD</last_name>
    <phone>86-20-87343117</phone>
    <phone_ext>86-20-87343117</phone_ext>
    <email>Chminsh@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>min-shan chen, MD</last_name>
      <phone>86-20-87343117</phone>
      <phone_ext>86-20-87343117</phone_ext>
      <email>Chminsh@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>min-shan chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>yao-jun zhang, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321-8.</citation>
    <PMID>16495695</PMID>
  </results_reference>
  <results_reference>
    <citation>Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol. 2001;11(6):914-21.</citation>
    <PMID>11419162</PMID>
  </results_reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>July 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2008</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>cancer canter, Sun Yat-sen University</name_title>
    <organization>cancer canter, Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>liver cancer</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>thalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

